Get App

Novartis' cancer treatment Kymriah gets Japan nod at cost of $305,800

The Swiss drugmaker aims to use the one-time personalised therapy in Japan for children and young people with acute lymphoblastic leukemia (ALL) and adult patients with diffuse large B-cell lymphoma (DLBCL).
  • Published On May 15, 2019 at 08:37 AM IST
Read by: 100 Industry Professionals
Reader Image Read by 100 Industry Professionals
TOKYO: A Japanese government panel approved Novartis' cancer treatment Kymriah at a price of 33.5 million yen ($305,800) on Wednesday, marking the entry of so-called CAR-T therapy in the country.

The Swiss drugmaker aims to use the one-time personalised therapy in Japan for children and young people with acute lymphoblastic leukemia (ALL) and adult patients with diffuse large B-cell lymphoma (DLBCL).

Kymriah works by removing disease fighting T-cells from individual patients, modifying them to attack cancer, and then re-infusing them back into the patients. ($1 = 109.5400 yen)

  • Published On May 15, 2019 at 08:37 AM IST
Be the first one to comment.
Comment Now

COMMENTS

Comment Now Read Comment (1)

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles
Scan to download App